NDAORALTABLET
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
SOTYKTU (deucravacitinib) by Bristol Myers Squibb is tyrosine kinase 2 inhibitors [moa]. First approved in 2022.
Drug data last refreshed 13h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOTYKTU (deucravacitinib) is an oral tyrosine kinase 2 inhibitor approved in September 2022 by Bristol Myers Squibb. It represents a targeted small-molecule approach to modulating immune-mediated inflammatory pathways through selective TYK2 inhibition.
$0.034BPart D
Peak16.4 years to LOEProduct is in peak commercialization phase with ~$34M Part D spending in 2023; Medical Affairs team expansion likely underway to support peak market penetration.
Mechanism of Action
Tyrosine Kinase 2 Inhibitors
Pharmacologic Class:
Tyrosine Kinase 2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
Started Dec 2026
2,300 enrolled
Systemic Lupus ErythematosusSjögren's DiseasePsoriasis+1 more
Deucravacitinib in the Treatment of Cicatricial Alopecias
Started May 2026
20 enrolled
Central Centrifugal Cicatricial AlopeciaFrontal Fibrosing Alopecia
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Started Feb 2026
35 enrolled
Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Started Dec 2025
366 enrolled
Plaque Psoriasis
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Started Sep 2025
3,040 enrolled
Plaque Psoriasis
Worked on SOTYKTU at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.